You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):抗腫瘤類重點產品“鹽酸多柔比星脂質體注射液”通過一致性評價
格隆匯 05-11 18:39

格隆匯5月11日丨石藥集團(01093.HK)發佈公吿,公司附屬公司石藥集團歐意藥業有限公司開發的“鹽酸多柔比星脂質體注射液(10ml:20mg)”(商品名:多美素)已獲中國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價,為國內該品種首個通過一致性評價的產品。

根據披露,鹽酸多柔比星是一種蒽環類抗生素,屬廣譜抗腫瘤藥,具有抑制DNA、RNA和蛋白合成的細胞毒作用,可用於低CD4(<200CD4淋巴細胞/mm 3 )及有廣泛皮膚粘膜內臟疾病的與艾滋病相關的卡波氏肉瘤(AIDS-KS)患者。該產品可用作一線全身化療藥物,或者用作治療病情有進展的AIDS-KS患者的二線化療藥物,也可用於不能耐受下述兩種以上藥物聯合化療的患者:長春新鹼、博萊黴素和多柔比星(或其他蒽環類抗生素)。多美素是集團抗腫瘤類重點產品之一,通過一致性評價標誌着集團在納米高端製劑技術領域達到國際先進水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account